Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Chronic viral cardiomyopathy is a disease where the cardiac muscle is attacked by a virus and
this may result in a reduction in the output of the heart (pump function) thereby causing
complaints such as chest pain, shortness of breath and palpitations.
Betaferon (interferon beta-1b) is marketed for the treatment of Multiple Sclerosis already,
but until now, it has not been proven whether it is also effective in patients with chronic
viral myocardial disease.
This study will be conducted to examine the efficacy and safety of Betaferon in patients with
this disease. The aim of the treatment is to eliminate the virus from the heart so that the
heart function and clinical status can gradually improve.